A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design

American Heart Journal

Volumn 161, Issue 1, 2011, Pages

  Preiss, David ^a   Sattar, Naveed ^a   McMurray, John J ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; DIABETES MELLITUS; EMBASE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MEDLINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; STROKE; SYSTEMATIC REVIEW;

EID: 78650295935     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.10.019     Document Type: Article

References (45)

1. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
2. Home P.D., Pocock S.J., and Beck-Nielsen H. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
3. Solomon S.D., Pfeffer M.A., and McMurray J.J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas Circulation 114 2006 1028 1035
4. Singh A.K., Szczech L., and Tang K.L. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098 (Pubitemid 44749317)
5. Goldfine A.B. Assessing the cardiovascular safety of diabetes therapies N Engl J Med 359 2008 1092 1095
6. Food and Drug Administration (Center for Drug Evaluation and Research) Guidance for industry: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071627.pdf Last accessed 6 June 2009
7. Dinneen S.F., and Gerstein H.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus-a systematic overview of the literature Arch Intern Med 157 1997 1413 1418
8. Gerstein H.C., Mann J.F., and Yi Q. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 286 2001 421 426 (Pubitemid 32681484)
9. Lee C.D., Folsom A.R., and Pankow J.S. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction Circulation 109 2004 855 860 (Pubitemid 38252737)
10. Colhoun H.M., Betteridge D.J., and Durrington P.N. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
11. Ogawa H., Nakayama M., and Morimoto T. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
12. Sacco M., Pellegrini F., and Roncaglioni M.C. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 2003 3264 3272 (Pubitemid 37466885)
13. Bakris G.L., Gaxiola E., and Messerli F.H. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study Hypertension 44 2004 637 642 (Pubitemid 39435232)
14. Daly C.A., Fox K.M., and Remme W.J. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy Eur Heart J 26 2005 1369 1378
15. Shepherd J., Breazna A., and Barter P. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes-the Treating to New Targets (TNT) study Diabetes Care 29 2006 1220 1226 (Pubitemid 44125913)
16. Keech A., Colquhoun D., and Best J. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose-results from the LIPID trial Diabetes Care 26 2003 2713 2721 (Pubitemid 37205536)
17. Belch J., MacCuish A., and Campbell I. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
18. Dormandy J.A., Charbonnel B., and Eckland D.J.A. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
19. Serneri G.G.N., Coccheri S., and Marubini E. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study Eur Heart J 25 2004 1845 1852 (Pubitemid 39330236)
20. Keech A., Simes R.J., and Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
21. Gerstein H.C., Miller M.E., and Byington R.P. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559 (Pubitemid 351831356)
22. Patel A., MacMahon S., and Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572 (Pubitemid 351831357)
23. Cusick M., Meleth A.D., and Agron E. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes-Early Treatment Diabetic Retinopathy Study report no. 27 Diabetes Care 28 2005 617 625 (Pubitemid 40315322)
24. Duckworth W., Abraira C., and Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
25. Gerstein H.C., Yusuf S., and Mann J.F.E. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259 (Pubitemid 30068516)
26. Collins R., Armitage J., and Parish S. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
27. Collins R., Armitage J., and Parish S. Comments on the MRC/BHF Heart Protection Study-authors' reply Lancet 362 2003 744 745 (Pubitemid 37101076)
28. Lindholm L.H., Ibsen H., and Dahlof B. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 1004 1010 (Pubitemid 34286537)
29. Whelton P.K., Barzilay J., and Cushman W.C. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia-Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 2005 1401 1409 (Pubitemid 40973423)
30. Sjolie A.K. Baseline data from the Diabetic Retinopathy Candesartan Trials Programme Invest Ophthalmol Vis Sci 46 2005 387-B361
31. Sjolie A.K., Klein R., and Porta M. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet 372 2008 1385 1393
32. Ruggenenti P., Fassi A., and Ilieva A.P. Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 2004 1941 1951 (Pubitemid 39447135)
33. Marre M., Lievre M., and Chatellier G. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) Br Med J 328 2004 495 499 (Pubitemid 38293609)
34. Berl T., Hunsicker L.G., and Lewis J.B. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial J Am Soc Nephrol 16 2005 2170 2179 (Pubitemid 41716450)
35. Lewis E.J., Hunsicker L.G., and Clarke W.R. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
36. Brenner B.M., Cooper M.E., and de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869 (Pubitemid 32927514)
37. Kahn S.E., Haffner S.M., and Heise M.A. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
38. Viberti G., Lachin J., and Holman R. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe Diabet Med 23 2006 1289 1294 (Pubitemid 44787790)
39. Turner R.C., Holman R.R., and Cull C.A. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
40. Turner R.C., Holman R.R., and Stratton I.M. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
41. Mancia G., Brown M., and Castaigne A. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) Hypertension 41 2003 431 436 (Pubitemid 36314612)
42. Dasgupta A., Steinhubl S.R., and Bhatt D.L. CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial) Am J Cardiol 103 2009 1359 1363
43. Bland J.M., and Kerry S.M. Statistics notes-weighted comparison of means Br Med J 316 1998 129
44. Haffner S.M., Lehto S., and Ronnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234 (Pubitemid 28350165)
45. Evans J.M.M., Wang J.X., and Morris D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies Br Med J 324 2002 939A 942A